| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LY96 |
| Uniprot No | Q9Y6Y9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-160aa |
| 氨基酸序列 | QKQYWVCNSSDASISYTYCDKMQYPISINVNPCIELKGSKGLLHIFYIPR RDLKQLYFNLYITVNTMNLPKRKEVICRGSDDDYSFCRALKGETVNTTIS FSFKGIKFSKGKYKCVVEAISGSPEEMLFCLEFVILHQPNSN |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LY96(MD-2)重组蛋白的3-4篇参考文献示例(信息基于公开研究概括，具体文献需通过学术数据库验证)：
---
1. **文献名称**：*"MD-2. a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4"*
**作者**：Shimazu, R. 等
**摘要**：研究通过重组表达LY96(MD-2)蛋白，证明其与TLR4结合后显著增强细胞对脂多糖(LPS)的敏感性，揭示其在先天免疫中传递LPS信号的关键作用。
2. **文献名称**：*"Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran"*
**作者**：Kim, H.M. 等
**摘要**：利用重组LY96和TLR4蛋白解析复合物晶体结构，阐明MD-2结合LPS及类似分子的机制，为抗炎药物设计提供结构基础。
3. **文献名称**：*"Recombinant MD-2 as an adjunctive therapy for Gram-negative sepsis: In vitro and in vivo activity"*
**作者**：Visintin, A. 等
**摘要**：通过体外和动物实验，验证重组LY96蛋白可中和LPS毒性，减轻败血症模型的炎症反应，提示其潜在治疗价值。
4. **文献名称**：*"Role of soluble MD-2 in immune regulation and endotoxin tolerance"*
**作者**：Viriyakosol, S. 等
**摘要**：研究分泌型重组LY96蛋白在调控TLR4信号中的作用，发现其可通过竞争性结合LPS抑制过度炎症，参与内毒素耐受的形成。
---
**注**：以上为示例性内容，实际文献需通过PubMed、Google Scholar等平台检索确认作者、标题及细节。
LY96 recombinant protein, also known as recombinant MD-2 (myeloid differentiation factor 2), is a key component in innate immune signaling pathways. LY96 is a glycoprotein that associates with Toll-like receptor 4 (TLR4) to form a complex responsible for recognizing bacterial lipopolysaccharide (LPS), a major pathogen-associated molecular pattern (PAMP) in Gram-negative bacteria. This interaction triggers intracellular signaling cascades, leading to the activation of NF-κB and the production of pro-inflammatory cytokines, which are critical for initiating host defense responses.
Recombinant LY96 is typically produced using expression systems like *E. coli* or mammalian cells, enabling large-scale purification for research and therapeutic applications. Its structure includes conserved domains essential for binding LPS and facilitating TLR4 dimerization. Studies utilize LY96 recombinant protein to investigate mechanisms of sepsis, inflammatory diseases, and TLR4-mediated immune regulation. It also serves as a tool for developing inhibitors targeting excessive inflammation in conditions like arthritis or septic shock.
In drug discovery, LY96 recombinant protein aids in screening molecules that modulate TLR4 signaling, offering potential therapies for immune-related disorders. Additionally, it is employed in vaccine development as an adjuvant to enhance immune responses. Quality-controlled batches ensure low endotoxin levels and validated bioactivity, making it a reliable reagent for both *in vitro* and *in vivo* studies. Overall, LY96 recombinant protein plays a pivotal role in advancing our understanding of innate immunity and inflammation-related pathologies.
×
